Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 4, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2025 financial results.  

The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website.  A replay of the webcast will be available on Corvus’ website for 90 days. 

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.

INVESTOR CONTACT: 
Leiv Lea 
Chief Financial Officer 
Corvus Pharmaceuticals, Inc. 
+1-650-900-4522 
llea@corvuspharma.com   

MEDIA CONTACT: 
Sheryl Seapy 
Real Chemistry 
+1-949-903-4750 
sseapy@realchemistry.com